FTC warns pharma industry on improperly listed patents
hapabapa

The Federal Trade Commission has put the pharmaceutical industry on notice that it will not tolerate what it calls patents that are improperly listed with the US FDA as it could harm generic competition.
The FTC issued a policy statement Thursday indicating that companies could face legal action for improperly listing drug patents in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, colloquially known as the "Orange Book."

If a pharma lists a brand drug patent in the Orange Book, it can lead to a statutory stay that prevents competing drugs -- generics -- for up to 30 months.
The FTC noted that improper patent listings "may unlawfully delay generic competition for years and disincentivize generic manufacturers from trying to come to market with lower cost alternatives at all," adding that these listings have likely been negatively impacting pharmaceutical markets for decades.
Major pharma companies: Pfizer (NYSE:PFE), Merck (NYSE:MRK), Eli Lilly (LLY), Bristol-Myers Squibb (NYSE:BMY), Johnson & Johnson (NYSE:JNJ), Amgen (AMGN) and Gilead Sciences.


More on pharmaceutical companies

Pfizer Vs. Gilead Sciences: COVID-19 Battle Of Pharma Titans
Pfizer: Still Attractive Despite Recent Acquisitions
Janssen to be renamed Johnson & Johnson Innovative Medicine
Bristol Myers to double registrational assets over 18 months
Barclays projects over $5B COVID booster sales in fall 2023